Trial Profile
An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Lutetium 177 satoreotide tetraxetan (Primary)
- Indications Carcinoid tumour; Gastrointestinal cancer; Lung cancer; Neuroendocrine tumours; Pancreatic cancer; Paraganglioma; Phaeochromocytoma
- Focus Adverse reactions
- Sponsors Ipsen
- 01 Dec 2023 Results assessing safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours, published in the European Journal of Nuclear Medicine and Molecular Imaging.
- 28 Sep 2023 According to an Ariceum Therapeutics Media Release, results of this study published in he European Journal of Nuclear Medicine and Molecular Imaging.
- 28 Sep 2023 Results presented in an Ariceum Therapeutics Media Release.